Country Access Report
Cyprus maintains a restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, most tryptamines and phenethylamines) with no routine authorised medical use outside clinical research. Ketamine is used clinically (including in research) and esketamine (Spravato) is authorised across the EU — access and public reimbursement in Cyprus is limited and dependent on national formulary / HIO (GeSY) decisions or private-pay arrangements and specialised clinic availability.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under national drug-scheduling laws, with no authorized medical use outside of approved clinical research. Evidence and public reporting indicate possession, sale and use of psilocybin remain illegal in Cyprus (criminal penalties apply by class), and there is no established public reimbursement or authorised medical psilocybin program. [1] [2]
Compound Access
Currently classified among the highest-risk controlled substances in Cyprus’s drug scheduling (Class A) and has no authorised medical pathway or reimbursement outside of tightly controlled clinical trials. Routine medical prescription, possession or sale is prohibited. [1]
Compound Access
Esketamine nasal spray (Spravato) received a marketing authorisation valid throughout the EU on 18 December 2019 via the European Commission; the EMA summary and EPAR describe its indication for adults with treatment‑resistant major depressive disorder in combination with an SSRI/SNRI and special supervised administration requirements. Access in Cyprus therefore is technically permitted under EU authorisation, but inclusion in public reimbursement lists (the national formulary under the Health Insurance Organization / GeSY) and practical availability depend on national pricing/reimbursement decisions and provider arrangements. There is no evidence of an automatic, universal public reimbursement for Spravato in Cyprus — access will generally require (a) a prescribing psychiatrist, (b) treatment provision in an authorised supervised setting (per the EU/EMA conditions), and (c) either private payment or case-by-case approval through national reimbursement procedures or specialty funding channels. Citations: EMA authorisation and product information for Spravato. [1] Additionally, national reimbursement and formulary inclusion in Cyprus is governed by HIO/GeSY processes and a national formulary committee; reimbursement decisions are not automatic following EU authorisation. [2]
Compound Access
Ketamine is an established medical anaesthetic and is used off‑label in psychiatry (intravenous and intramuscular regimens) for severe or treatment‑resistant depression in many countries; in Cyprus ketamine is available in medical settings and is the subject of investigator‑led clinical trials and growing clinical practice in specialty clinics. Clinical research activity in Cyprus includes registered ketamine interventional trials (for example the PROUD ketamine trial registered in the EU Clinical Trials Register and run in cooperation with Cypriot institutions), and local academic publications and clinic reports note ketamine’s off‑label psychiatric use in Cyprus. Public reimbursement for off‑label ketamine when used for psychiatric indications is not an established, routine pathway and typically depends on the prescribing institution, whether treatment occurs in a public hospital setting under GeSY/HIO rules, and negotiated approval; many patients access ketamine psychiatric treatments via private clinics or research studies. Citations: University/clinical trial reporting and local academic reviews documenting ketamine clinical trials and practice in Cyprus. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no routine medical access or public reimbursement for DMT in Cyprus. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No authorised medical pathway or reimbursement exists in Cyprus. [1]
Compound Access
Compound Access
Currently treated as illegal under national narcotics and psychotropic substances legislation when containing scheduled tryptamine DMT; there is no authorised medical use or reimbursement in Cyprus outside approved research. Ceremonial or sacramental use would still be subject to national controlled‑substance prohibitions. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug schedules; no authorised medical mescaline program or public reimbursement exists in Cyprus outside approved clinical research. [1]
Compound Access
Last updated 15 Jul 2026. Source links come from the medical access guide.